News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
748,934 Results
Type
Article (60942)
Company Profile (487)
Press Release (687505)
Section
Business (210722)
Career Advice (3293)
Deals (36274)
Drug Delivery (125)
Drug Development (85084)
Employer Resources (182)
FDA (17390)
Job Trends (15863)
News (360305)
Policy (35985)
Tag
Academia (2910)
Alliances (53499)
Alzheimer's disease (1410)
Approvals (17342)
Artificial intelligence (236)
Bankruptcy (346)
Best Places to Work (12454)
Biotechnology (357)
Breast cancer (241)
Cancer (1830)
Cardiovascular disease (146)
Career advice (2783)
CAR-T (140)
Cell therapy (403)
Clinical research (68091)
Collaboration (716)
Compensation (368)
COVID-19 (2798)
C-suite (174)
Data (1672)
Diabetes (231)
Diagnostics (6665)
Earnings (83768)
Employer resources (160)
Events (121813)
Executive appointments (598)
FDA (18334)
Funding (648)
Gene therapy (284)
GLP-1 (760)
Government (4983)
Healthcare (20424)
Infectious disease (2916)
Inflammatory bowel disease (134)
Interviews (637)
IPO (16778)
Job creations (3926)
Job search strategy (2284)
Layoffs (497)
Legal (8474)
Lung cancer (273)
Manufacturing (267)
Medical device (14149)
Medtech (14154)
Mergers & acquisitions (19904)
Metabolic disorders (626)
Neuroscience (1862)
NextGen: Class of 2025 (7356)
Non-profit (4882)
Northern California (2134)
Obesity (351)
Opinion (258)
Patents (173)
People (59565)
Phase I (21134)
Phase II (29780)
Phase III (22558)
Pipeline (740)
Postmarket research (2902)
Preclinical (9119)
Radiopharmaceuticals (263)
Rare diseases (362)
Real estate (6370)
Regulatory (24417)
Research institute (2590)
Resumes & cover letters (521)
Southern California (1835)
Startups (3825)
United States (19432)
Vaccines (700)
Weight loss (263)
Date
Today (104)
Last 7 days (652)
Last 30 days (2806)
Last 365 days (36647)
2025 (4756)
2024 (37425)
2023 (42157)
2022 (53478)
2021 (58213)
2020 (57002)
2019 (50338)
2018 (38220)
2017 (35427)
2016 (35649)
2015 (41326)
2014 (34575)
2013 (30110)
2012 (31928)
2011 (31989)
2010 (29919)
Location
Africa (1023)
Arizona (199)
Asia (44235)
Australia (7491)
California (4944)
Canada (1743)
China (416)
Colorado (227)
Connecticut (250)
Europe (101316)
Florida (707)
Georgia (175)
Illinois (521)
Indiana (275)
Maryland (794)
Massachusetts (3861)
Michigan (220)
Minnesota (349)
New Jersey (1404)
New York (1405)
North Carolina (957)
Northern California (2134)
Ohio (185)
Pennsylvania (1118)
South America (1384)
Southern California (1835)
Texas (713)
Utah (150)
Washington State (500)
748,934 Results for "the medicines and healthcare products regulatory agency mhra".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
February 14, 2025
·
9 min read
Press Releases
Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
September 3, 2024
·
4 min read
Biotech Beach
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), today announced The Medicines and Healthcare products Regulatory Agency (MHRA) authorization of NULIBRY.
April 16, 2024
·
6 min read
GLP-1
UK’s MHRA Finds No Risk of Suicidal Ideation, Self-Harm With GLP-1 Drugs
Like its U.S. and European counterparts, Britain’s Medicines and Healthcare Products Regulatory Agency found no conclusive link between the use of GLP-1s and a heightened risk of suicidal and self-injury thoughts.
September 5, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
February 3, 2025
·
5 min read
Biotech Beach
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has approved REZZAYO (rezafungin acetate) for the treatment of invasive candidiasis in adults.
January 29, 2024
·
5 min read
Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License
Emergex Vaccines Holding Limited announced that Emergex has received its Manufacturing and Import Authorisation Investigational Medicinal Product from the UK’s Medicines and Healthcare Products Regulatory Agency to advance its novel T cell-priming vaccine candidates into clinical production.
June 18, 2024
·
4 min read
Drug Development
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
GRI Bio, Inc. today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the UK.
March 4, 2024
·
7 min read
Press Releases
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
January 7, 2025
·
10 min read
BioCapital
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”) announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer.
December 21, 2023
·
7 min read
1 of 74,894
Next
